Debanjana Chatterjee
Stock Analyst at Jones Trading
(2.86)
# 1,735
Out of 4,960 analysts
10
Total ratings
88.89%
Success rate
16.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $13.91 | +72.54% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $7.11 | +279.75% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $28.05 | +39.04% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $13.41 | +123.71% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $9.94 | +131.39% | 1 | Mar 13, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $17.38 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $23.12 | +98.96% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $10.52 | +289.73% | 1 | Sep 17, 2024 |
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $13.91
Upside: +72.54%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $7.11
Upside: +279.75%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $28.05
Upside: +39.04%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $13.41
Upside: +123.71%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $9.94
Upside: +131.39%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $17.38
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $23.12
Upside: +98.96%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $10.52
Upside: +289.73%